SLC5A2 and Abnormal blood ion concentration: Furthermore, the authors highlight the perioperative hematologic, metabolic, and electrolyte disorders that may arise from disease and cardiac-target therapies such as tafamidis and sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors).